162 related articles for article (PubMed ID: 17343986)
1. Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma.
Zalatnai A
Cancer Treat Rev; 2007 May; 33(3):289-98. PubMed ID: 17343986
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007.
Saif MW
JOP; 2007 Jul; 8(4):365-73. PubMed ID: 17625289
[TBL] [Abstract][Full Text] [Related]
3. Novel therapies for pancreatic adenocarcinoma.
Pino SM; Xiong HQ; McConkey D; Abbruzzese JL
Curr Oncol Rep; 2004 May; 6(3):199-206. PubMed ID: 15066231
[TBL] [Abstract][Full Text] [Related]
4. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.
Saif MW
JOP; 2008 Mar; 9(2):91-8. PubMed ID: 18326919
[TBL] [Abstract][Full Text] [Related]
5. Novel therapies for pancreatic adenocarcinoma.
Pino SM; Xiong HQ; McConkey D; Abbruzzese JL
Curr Gastroenterol Rep; 2004 Apr; 6(2):119-25. PubMed ID: 15191689
[TBL] [Abstract][Full Text] [Related]
6. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Burris H; Rocha-Lima C
Oncologist; 2008 Mar; 13(3):289-98. PubMed ID: 18378539
[TBL] [Abstract][Full Text] [Related]
7. [Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer].
Ryu JK
Korean J Gastroenterol; 2015 Sep; 66(3):150-3. PubMed ID: 26387697
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
Zafar SF; El-Rayes BF
Am J Clin Oncol; 2014 Apr; 37(2):194-200. PubMed ID: 22643564
[TBL] [Abstract][Full Text] [Related]
9. Novel agents for the treatment of adenocarcinoma of the pancreas.
Mackenzie RP; McCollum AD
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1473-85. PubMed ID: 19828009
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006.
Saif MW
JOP; 2006 Jul; 7(4):337-48. PubMed ID: 16832131
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
12. Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine.
Rosenberg L
Int J Pancreatol; 1997 Oct; 22(2):81-93. PubMed ID: 9387029
[TBL] [Abstract][Full Text] [Related]
13. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Li J; Saif MW
JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
[TBL] [Abstract][Full Text] [Related]
16. [Contribution of gemcitabine in the treatment of advanced pancreatic cancer].
Brunet R; Fonck M
Rev Med Interne; 1999 Sep; 20(9):816-20. PubMed ID: 10522306
[TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].
Conroy T; Mitry E
Bull Cancer; 2011 Dec; 98(12):1439-46. PubMed ID: 22133915
[TBL] [Abstract][Full Text] [Related]
18. Front-line therapy of advanced pancreatic cancer.
Kindler HL
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S33-6. PubMed ID: 16399428
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis.
Tian W; Ding W; Kim S; Xu X; Pan M; Chen S
Pancreatology; 2013; 13(4):415-22. PubMed ID: 23890141
[TBL] [Abstract][Full Text] [Related]
20. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
Singh A; Xu J; Mattheolabakis G; Amiji M
Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
